The company received the approval to market the drug in various strengths -- 1 mg, 2 mg, 2.5 mg, 3 mg, 4mg, 5mg 6mg, 7.5 mg and 10 mg -- it informed the Stock Exchanges.
Cadila plans to launch the anti-coagulant, which falls in the cardiovascular segment, within a month.
The branded sales of the product in 2005 were over $210 million.
The company would be sourcing the Active Pharmaceutical Ingredients from its own USFDA-approved manufacturing facility at Dabhasa, Gujarat.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
